Nyxoah S.A. (NASDAQ:NYXH) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Nyxoah S.A. (NASDAQ:NYXH) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $20.60.

NYXH has been the subject of a number of analyst reports. Cantor Fitzgerald raised their price target on Nyxoah from $10.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, February 9th. Oppenheimer raised their price target on Nyxoah from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. Stifel Nicolaus raised their price target on Nyxoah from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of Nyxoah in a report on Wednesday, March 20th. Finally, Piper Sandler raised their price target on Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th.

Nyxoah Price Performance

Shares of NYXH opened at $9.30 on Friday. The company has a quick ratio of 4.50, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The stock has a 50 day moving average of $13.72 and a 200 day moving average of $8.58. Nyxoah has a 12 month low of $4.00 and a 12 month high of $20.00.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Nyxoah had a negative return on equity of 38.58% and a negative net margin of 993.28%. The company had revenue of $1.96 million during the quarter, compared to the consensus estimate of $2.01 million. As a group, analysts expect that Nyxoah will post -1.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP raised its stake in Nyxoah by 44.6% during the 2nd quarter. ExodusPoint Capital Management LP now owns 18,758 shares of the company’s stock valued at $150,000 after buying an additional 5,787 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Nyxoah during the 1st quarter valued at $965,000. AXA S.A. raised its stake in Nyxoah by 1.4% during the 1st quarter. AXA S.A. now owns 217,000 shares of the company’s stock valued at $1,621,000 after buying an additional 3,000 shares during the last quarter. Millennium Management LLC purchased a new stake in Nyxoah during the 4th quarter valued at $51,000. Finally, Sei Investments Co. purchased a new stake in Nyxoah during the 2nd quarter valued at $265,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.